Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Palliation
Is it appropriate to offer combination lung SBRT and immunotherapy for oligometastatic melanoma outside of a clinical trial?
If so, can these be administered concurrently?
Related Questions
Do you have a 15 fraction constraint for the LADA?
Do you constrain heterogeneity or hotspots when delivering spine SBRT for bone metastases?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
Would you consider palliative RT in the setting of tumor causing osteonecrosis in an elderly patient?
Would you consider spine re-irradiation after Pluvicto?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
Is there a role for radiation in palliating malignant small bowel obstruction?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
What normal tissue dose constraints do you use when delivering up to 3 cycles of the palliative quad shot regimen for gynecologic pelvic malignancies?